Elevated first-trimester biomarker increases preeclampsia risk, indicating its potential for prenatal risk stratification.
Elevated first-trimester PIV is independently and linearly associated with increased risk of PE, with no identifiable threshold effect. These findings highlight the potential utility of PIV as an accessible, inflammation-based biomarker for early PE risk stratification. Future prospective studies are warranted to validate its clinical applicability and explore integration into prenatal screening protocols.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: